IL33 and cancer: Taken together, our findings suggest that the enhanced intestinal proliferative and protumorigenic phenotypes observed in Rbm47-IKO mice are counterbalanced by augmented antioxidative adaptations and upregulation of pathways including Il-33 and its downstream targets that together protect these mice against inflammation and colitis-associated cancer after AOM/DSS treatment.